CWA 17379 and the Future of On-Road Emissions Testing: An Interview with Nick Molden

CWA 17379 and the Future of On-Road Emissions Testing: An Interview with Nick Molden

Watch Now

Nick Molden is the founder and CEO of Emissions Analytics, which specialises in the measurement of emissions and fuel efficiency for passenger and commercial vehicles, as well as non-road mobile machinery. Molden has been a persistent advocate for independent emissions testing, has helped to develop standards and with his co-founder, Massimo Fedeli, established Allow Independent Road-testing, or AIR, a non-profit which produces an online emissions index, the AIR Index, that enables consumers, fleet managers and policy makers to make more informed choices about the vehicles they use every day.  

Our reporter sat down with Nick to talk about the creation of the CWA 17379 standard, the state of on-road emissions and the value of portable emission monitors.

More on the speakers

Author headshot

Nick Molden

Emissions Analytics

Nick Molden is the founder of Emissions Analytics, a company that pioneered the use of real-world, on-road testing of vehicles to understand their actual levels of pollutant and carbon dioxide emissions. Through the largest programme of independent testing so far conducted, it became possible to understand the true background to and consequences of the ‘Dieselgate’ scandal.

More on the moderators

Author headshot

Jed Thomas

International Labmate Ltd.

Currently, Jed Thomas serves as a Content Editor at International Labmate.

IET 36.3 May

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Labmate Online
Faecal microbiota transplantation shows early promise for peanut allergy treatment
Explore more Arrow
Pollution Solutions Online
Leading UK biogas operator places first orders for new FlowSep technology
Explore more Arrow
Petro Online
Smart fuel lubricity testers for modern labs
Explore more Arrow
Chromatography Today
Unlock high-resolution analysis of therapeutic oligonucleotides
Explore more Arrow